Laurus Labs Limited
NSE:LAURUSLABS.NS
499.35 (INR) • At close November 8, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Laurus Labs Limited |
Symbool | LAURUSLABS.NS |
Munteenheid | INR |
Prijs | 499.35 |
Beurswaarde | 269,229,046,650 |
Dividendpercentage | 0.27% |
52-weken bereik | 360.85 - 518 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Dr. Satyanarayana Chava M.Sc., Ph.D. |
Website | https://www.lauruslabs.com |
An error occurred while fetching data.
Over Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (INR)
Cijfers zijn in miljoenen (INR)